Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease

R. J. Vermeulen; E. C. Wolters; G. Tissingh; J. Booij; A. G. Janssen; J. Habraken; E. Sokole-Busemann; J. C. Stoof; E. A. van Royen

doi:https://doi.org/10.1016/0969-8051(95)02020-9

Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease

R. J. Vermeulen, E. C. Wolters, G. Tissingh, J. Booij, A. G. Janssen, J. Habraken, E. Sokole-Busemann, J. C. Stoof, E. A. van Royen

Other Departments

Research output: Contribution to journal › Article › Academic › peer-review

37 Citations (Scopus)

Abstract

The main neuropathological feature in Parkinson's disease (PD) is a severe degeneration of the dopaminergic neurons in the substantia nigra resulting in a loss of dopamine in the striatum. Recently, a new radioligand (beta-CIT) for single photon emission computed tomography (SPECT) became available for in vivo imaging of the dopamine transporter on nerve endings of dopaminergic neurons in the striatum. The present results demonstrate that [123I]-beta-CIT SPECT allows a discrimination between early and late PD patients. In our opinion, these preliminary data suggest that [123I]-beta-CIT SPECT should be used from now on in longitudinal studies (such as the DATATOP study) in which the effects of (putative) neuroprotective interventions in PD are monitored

Original language	English
Pages (from-to)	985-991
Journal	Nuclear medicine and biology
Volume	22
Issue number	8
DOIs	https://doi.org/10.1016/0969-8051(95)02020-9
Publication status	Published - 1995

Access to Document

https://doi.org/10.1016/0969-8051(95)02020-9

Cite this

@article{4f0bb3362eb3488fb086300b4359cf21,

title = "Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease",

abstract = "The main neuropathological feature in Parkinson's disease (PD) is a severe degeneration of the dopaminergic neurons in the substantia nigra resulting in a loss of dopamine in the striatum. Recently, a new radioligand (beta-CIT) for single photon emission computed tomography (SPECT) became available for in vivo imaging of the dopamine transporter on nerve endings of dopaminergic neurons in the striatum. The present results demonstrate that [123I]-beta-CIT SPECT allows a discrimination between early and late PD patients. In our opinion, these preliminary data suggest that [123I]-beta-CIT SPECT should be used from now on in longitudinal studies (such as the DATATOP study) in which the effects of (putative) neuroprotective interventions in PD are monitored",

author = "Vermeulen, {R. J.} and Wolters, {E. C.} and G. Tissingh and J. Booij and Janssen, {A. G.} and J. Habraken and E. Sokole-Busemann and Stoof, {J. C.} and {van Royen}, {E. A.}",

year = "1995",

doi = "https://doi.org/10.1016/0969-8051(95)02020-9",

language = "English",

volume = "22",

pages = "985--991",

journal = "Nuclear medicine and biology",

issn = "0969-8051",

publisher = "Elsevier Inc.",

number = "8",

}

TY - JOUR

T1 - Evaluation of [123I] beta-CIT binding with SPECT in controls, early and late Parkinson's disease

AU - Vermeulen, R. J.

AU - Wolters, E. C.

AU - Tissingh, G.

AU - Booij, J.

AU - Janssen, A. G.

AU - Habraken, J.

AU - Sokole-Busemann, E.

AU - Stoof, J. C.

AU - van Royen, E. A.

PY - 1995

Y1 - 1995

N2 - The main neuropathological feature in Parkinson's disease (PD) is a severe degeneration of the dopaminergic neurons in the substantia nigra resulting in a loss of dopamine in the striatum. Recently, a new radioligand (beta-CIT) for single photon emission computed tomography (SPECT) became available for in vivo imaging of the dopamine transporter on nerve endings of dopaminergic neurons in the striatum. The present results demonstrate that [123I]-beta-CIT SPECT allows a discrimination between early and late PD patients. In our opinion, these preliminary data suggest that [123I]-beta-CIT SPECT should be used from now on in longitudinal studies (such as the DATATOP study) in which the effects of (putative) neuroprotective interventions in PD are monitored

AB - The main neuropathological feature in Parkinson's disease (PD) is a severe degeneration of the dopaminergic neurons in the substantia nigra resulting in a loss of dopamine in the striatum. Recently, a new radioligand (beta-CIT) for single photon emission computed tomography (SPECT) became available for in vivo imaging of the dopamine transporter on nerve endings of dopaminergic neurons in the striatum. The present results demonstrate that [123I]-beta-CIT SPECT allows a discrimination between early and late PD patients. In our opinion, these preliminary data suggest that [123I]-beta-CIT SPECT should be used from now on in longitudinal studies (such as the DATATOP study) in which the effects of (putative) neuroprotective interventions in PD are monitored

U2 - https://doi.org/10.1016/0969-8051(95)02020-9

DO - https://doi.org/10.1016/0969-8051(95)02020-9

M3 - Article

C2 - 8998476

SN - 0969-8051

VL - 22

SP - 985

EP - 991

JO - Nuclear medicine and biology

JF - Nuclear medicine and biology

IS - 8

ER -